Annovis Bio, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for ANVS, updated each market day.
ANVS AI Sentiment
AI predicts Annovis Bio, Inc. stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Annovis Bio, Inc.
Annovis Bio Inc is a late-stage clinical drug platform company addressing neurodegeneration, including Alzheimer's disease (AD) and Parkinson's disease (PD). The Company is developing its product candidate, buntanetap, a synthetically produced, orally administered, brain-penetrant small molecule designed to treat AD, PD, and potentially other chronic neurodegenerative diseases by inhibiting the synthesis of neurotoxic proteins and TDP43, which contribute to neurodegeneration and reduced axonal transport. Its pipeline includes buntanetap for chronic neurodegeneration, including AD, PD, and PDD, as well as in certain combination therapies, ANVS405 for acute neurodegeneration, and ANVS301 for AD.
Sector
Exchange
Market Cap
$45,935,524
Cap Tier
Employees
7
Headquarters
MALVERN, PA
Listed Since
Jan. 29, 2020
Website
ANVS Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ANVS Volatility
Annovis Bio, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
